It's always interesting to see the potential for resource shifts in one segment to the other as innovation flourishes.
Does anyone know the average medical/hospital healthcare costs for liver treatment patients due to Hep C?
I've liked Gilead for quite some time, and this is great news! But as important as the Hep C breakthrough is, Gilead has many, many other drugs in the pipeline for HIV/AIDS, cancer, rheumatoid arthritis, etc. The diversity of their R & D is what I think really sets them apart.
@Noreen,
Thanks for that info. Yes from what I read $14-$15B is about the market size. Pretty hefty! Explains the big pop in GILD yesterday. Today the stock is backing off a bit, down 1%.
Re: Hep C market
tokyogai
4/20/2012 9:12:07 AM
This just outlines what a big problem Hep C is. It is good to see that we as a civilization are making progress on thei horrible disease. It makes me what to support the drug industry in spite of some of their other business strategies.
Re: Hep C market
Dex
4/20/2012 9:08:02 AM
The other thing about Hep C is that it's the chief reason for liver transplants in the US. So a viable Hep C treatment will have a positive impact on health care costs overall if we can reduce the need for transplant surgeries.
This puts Hep C in perspective: Scott D. Holmberg, chief of the epidemiology and surveillance branch for viral hepatitis at the U.S. Centers for Disease Control and Prevention, reported at a major liver conference in November that the number of people who die with hepatitis C in the U.S. now exceeds the number of those who die of HIV/AIDS.
Market-research firm Decision Resources estimates the overall hepatitis C virus drug market will experience significant growth, expanding from almost $1.7 billion in 2010 to $14.4 billion in 2015 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Thereafter, the market will decrease to $11.2 billion in 2020, owing to a decline in the size of the treatment-eligible population due to declining prevalence and effective new regimens.
Decision Resources also estimates that by 2015, Gilead's GS-7977 Plus Ribavirin Will Displace the Current Proprietary Clinical Gold Standard, Telaprevir in Combination with Peg-IFNα/Ribavirin.
Re: Take over candidate?
Value Hiker
4/19/2012 8:48:17 PM
@Scott, who can be the potential buyer of Gilead: pfizer, merck, or BMY? But BMY seems won't buy Gilead due to its competitive acquisition of Inhibitex.
Yes I do though it's a big company would have to be a Big Pharma buy. But I don't think they will sell.
The blogs and comments posted on Investor Uprising do not reflect the views of Investor Uprising, PRNewswire, or its sponsors. Investor Uprising, PRNewswire, and its sponsors do not assume responsibility for any comments, claims, or opinions made by authors and bloggers. They are no substitute for your own research and should not be relied upon for trading or any other purpose.
Tweet This